Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YMN-A02
- Development stage
- Phase 1
- Lead developer
- West China Hospital of Sichuan University
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
YMN-A02 is a bifunctional mRNA-based therapeutic encapsulated in a proprietary lipid nanoparticle (TM10-LNP). It is designed to encode a fusion protein that simultaneously targets two key pathways of immune evasion in the tumor microenvironment: cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and transforming growth factor-beta (TGF-β). By combining a CTLA-4 antibody with a TGF-β trap, YMN-A02 aims to activate antitumor immune responses and reverse immune tolerance, particularly in patients with advanced hepatocellular carcinoma (HCC) who have failed standard-of-care treatments. The drug is currently being evaluated in Phase I clinical trials by West China Hospital of Sichuan University.
- Other names
- YMN-A02 bifunctional RNA formulationYMN-A-02 bifunctional RNA formulationYMN-A 02 bifunctional RNA formulation
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)TGFB (GARP–latent transforming growth factor beta 1 complex)
Beyond the preview
Go deeper on YMN-A02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YMN-A02.